A- A A+

UK. Take Home Naloxone in the UK

Naloxone (provided under the brand names Prenoxad and Nyxoid in the UK) is a medication used to reverse opioid overdose. Since 2015, this medication has been more widely available in the UK as a ‘take home’ emergency medication. (2022)

https://naloxone.org.uk/

UK. ACMD Naloxone Review 

The Advisory Council on the Misuse of Drugs has undertaken a review of the availability and implementation of naloxone in the UK. (ACMD, UK, 17.06.2022)

https://www.gov.uk/government/publications/acmd-naloxone-review

UK. More work needed to increase availability of naloxone, says ACMD

More needs to be done to increase the availability and use of naloxone, according to a report from ACMD. 

Community pharmacies should be able to deliver take-home naloxone as well as interventions in managing opioid overdose, says the document, while data quality also needs to be improved to allow commissioners to properly monitor how the drug is being provided. (DDN – Drink and Drugs News, UK, 20.06.2022)

https://www.drinkanddrugsnews.com/more-work-needed-to-increase-availability-of-naloxone-says-acmd/

USA. Naloxone saves Lives

Clinicians play an important role in raising awareness about naloxone. Talk with your patients and their family, friends, and caregivers about the benefits of naloxone. Help reduce the stigma sometimes experienced with its use. (CDC Information and Resource Hub, Juni 2022)

https://www.cdc.gov/opioids/naloxone/index.html

Beliefs and misperceptions about naloxone and overdose among U.S. laypersons: a cross-sectional study. 

Agley J, Xiao Y, Eldridge L, Meyerson B, Golzarri-Arroyo L. 

BMC Public Health. 2022 May 10;22(1):924. doi: 10.1186/s12889-022-13298-3. PMID: 35538566; PMCID: PMC9086153.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086153/

Awareness and knowledge of the Good Samaritan Drug Overdose Act among people at risk of witnessing an overdose in British Columbia, Canada: a multi-methods cross sectional study. 

Ackermann E, Kievit B, Xavier J, Barbic S, Ferguson M, Greer A, Loyal J, Mamdani Z, Palis H, Pauly B, Slaunwhite A, Buxton JA. 

Subst Abuse Treat Prev Policy. 2022 May 25;17(1):42. doi: 10.1186/s13011-022-00472-4. PMID: 35614474; PMCID: PMC9131579.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131579/

Naloxone-associated pulmonary edema in a 3-year-old with opioid overdose. 

Grout S, Dave M, Lefort R. 

J Am Coll Emerg Physicians Open. 2022 May 23;3(3):e12740. doi: 10.1002/emp2.12740. PMID: 35619624; PMCID: PMC9127350.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127350/

Are thyrotropin-releasing hormone (TRH) and analog taltirelin viable reversal agents of opioid-induced respiratory depression? 

Algera MH, Cotten JF, van Velzen M, Niesters M, Boon M, Shoham DS, Dandrea KE, van der Schrier R, Dahan A. 

Pharmacol Res Perspect. 2022 Jun;10(3):e00974. doi: 10.1002/prp2.974. PMID: 35621218; PMCID: PMC9137104.

https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.974

Best practices for community-based overdose education and naloxone distribution programs: results from using the Delphi approach. 

Wenger LD, Doe-Simkins M, Wheeler E, Ongais L, Morris T, Bluthenthal RN, Kral AH, Lambdin BH. 

Harm Reduct J. 2022 May 28;19(1):55. doi: 10.1186/s12954-022-00639-z. PMID: 35643444; PMCID: PMC9145109.

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-022-00639-z

Take-Home Naloxone Kits: Attitudes and Likelihood-Of-Use Outcomes from a European Survey of Potential Overdose Witnesses. 

McDonald R, Breidahl S, Abel-Ollo K, Akhtar S, Clausen T, Day E, Kelleher M, McAuley A, Petersen H, Sefranek M, Thiesen H, Strang J. 

Eur Addict Res. 2022;28(3):220-225. doi: 10.1159/000521197. Epub 2022 Feb 3. PMID: 35114666.

https://www.karger.com/Article/FullText/521197

Naloxone administration—no balance without titration. 

Skulberg, A.K., Tylleskär, I. and Dale, O. (2022), 

Addiction. doi.org/10.1111/add.15947

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15947

Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study. 

Antoniou T, Men S, Tadrous M, Leece P, Munro C, Gomes T. 

Drug Alcohol Depend. 2022 Apr 26;236:109473. doi: 10.1016/j.drugalcdep.2022.109473. Epub ahead of print. PMID: 35523113.

https://www.sciencedirect.com/science/article/pii/S0376871622002101

Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders. 

Abdelal R, Raja Banerjee A, Carlberg-Racich S, Darwaza N, Ito D, Shoaff J, Epstein J. 

Harm Reduct J. 2022 May 20;19(1):49. doi: 10.1186/s12954-022-00627-3. PMID: 35596213; PMCID: PMC9122081.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122081/

NALtrain Newsletter 3 – Mai 2022

1) Daten und Fakten zu den Trainings 

2) Informationen zu den Materialien 

3) Bericht eines PEER-Trainings 

4) Vorstellung der Trainer*innen – Kerstin Dettmer

https://www.akzept.eu/wp-content/uploads/2022/05/NALtrainNewsletter3f.pdf

Schottland. Edinburgh taxi drivers to carry Naloxone kits to help prevent drug deaths

Edinburgh taxi drivers will soon be equipped with Naloxone in an effort to prevent drug overdoses in Scotland.

The move has been welcomed as life-saving by drug policy minister Angela Constance. (The Herald, Schottland, 24.05.2022)

https://www.heraldscotland.com/news/20162601.edinburgh-taxi-drivers-carry-naloxone-kits-help-prevent-drug-deaths/

If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study. 

Slocum S, Ozga JE, Joyce R, Walley AY, Pollini RA. 

BMC Public Health. 2022 Apr 13;22(1):735. doi: 10.1186/s12889-022-13078-z. PMID: 35418048; PMCID: PMC9006069.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006069/

Supporting people responding to overdoses. 

Marks C, Wagner KD. 

Lancet Public Health. 2022 Mar;7(3):e198-e199. doi: 10.1016/S2468-2667(22)00011-1. Epub 2022 Feb 10. PMID: 35151373.

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(22)00011-1/fulltext

Naloxone’s dose-dependent displacement of [11C]carfentanil and duration of receptor occupancy in the rat brain. 

Kang, Y., O’Conor, K.A., Kelleher, A.C. et al.

Sci Rep 12, 6429 (2022). doi.org/10.1038/s41598-022-09601-2

https://www.nature.com/articles/s41598-022-09601-2

Schottland. National naloxone programme Scotland: annual Monitoring report 2019/20 and 2020/21

An Official Statistics publication for Scotland. (Public Health Scotland, Schottland, 03.05.2022)

https://www.publichealthscotland.scot/publications/national-naloxone-programme-scotland-annual/national-naloxone-programme-scotland-monitoring-report-201920-202021/

An observational prospective cohort study of naloxone use at witnessed overdoses, Kazakhstan, Kyrgyzstan, Tajikistan, Ukraine. 

Dietze P, Gerra G, Poznyak V, Campello G, Kashino W, Dzhonbekov D, Kiriazova T, Nikitin D, Terlikbayeva A, Krupchanka D, Busse A. 

Bull World Health Organ. 2022 Mar 1;100(3):187-195. doi: 10.2471/BLT.21.286459. Epub 2022 Feb 3. PMID: 35261407; PMCID: PMC8886259.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886259/

Harm reduction in the Heartland: public knowledge and beliefs about naloxone in Nebraska, USA. 

Schlosser A, Habecker P, Bevins R. 

Harm Reduct J. 2022 Mar 4;19(1):22. doi: 10.1186/s12954-022-00606-8. PMID: 35246153; PMCID: PMC8894827.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894827/

Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City. 

Bennett AS, Scheidell J, Bowles JM, Khan M, Roth A, Hoff L, Marini C, Elliott L. 

Harm Reduct J. 2022 Mar 4;19(1):20. doi: 10.1186/s12954-022-00604-w. PMID: 35246165; PMCID: PMC8894821.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894821/

An Exploration of Narcan as a Harm Reduction Strategy and User's Attitudes toward Law Enforcement Involvement in Overdose Cases. 

Durieux J, Curtis A, Mirka M, Jefferis E, Felix C, Essel B. 

Int J Environ Res Public Health. 2022 Mar 8;19(6):3149. doi: 10.3390/ijerph19063149. PMID: 35328837; PMCID: PMC8954857.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954857/

Characteristics of and Experience Among People Who Use Take-Home Naloxone in Skåne County, Sweden. 

Troberg K, Isendahl P, Blomé MA, Dahlman D, Håkansson A. 

Front Public Health. 2022 Mar 10;10:811001. doi: 10.3389/fpubh.2022.811001. PMID: 35359781; PMCID: PMC8960176.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960176/

Assessment of Patient-Reported Naloxone Acquisition and Carrying With an Automated Text Messaging System After Emergency Department Discharge in Philadelphia. 

Agarwal AK, Sangha HK, Spadaro A, et al. 

JAMA Netw Open. 2022;5(3):e223986. doi:10.1001/jamanetworkopen.2022.3986

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790438

Perspectives from law enforcement officers who respond to overdose calls for service and administer naloxone. 

Smiley-McDonald HM, Attaway PR, Richardson NJ, Davidson PJ, Kral AH. 

Health Justice. 2022 Feb 25;10(1):9. doi: 10.1186/s40352-022-00172-y. PMID: 35212812; PMCID: PMC8874742.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874742/

Perspectives of Stakeholders of Equitable Access to Community Naloxone Programs: A Literature Review. 

Martignetti L, Sun W. 

Cureus. 2022 Jan 20;14(1):e21461. doi: 10.7759/cureus.21461. PMID: 35223245; PMCID: PMC8858082.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858082/

Pharmacological profiling of anti-fentanyl monoclonal antibodies in combination with naloxone in pre- and post-exposure models of fentanyl toxicity. 

Baehr CA, Wu MM, Pandit SG, Arias-Umana J, AuCoin D, Pravetoni M. 

J Pharmacol Exp Ther. 2022 Feb 13:JPET-AR-2021-001048. doi: 10.1124/jpet.121.001048. Epub ahead of print. PMID: 35153198.

https://jpet.aspetjournals.org/content/early/2022/02/13/jpet.121.001048.long

Schottland. National naloxone programme Scotland - Quarterly monitoring bulletin
Quarterly monitoring bulletin July to September (Q2) 2021 to 2022. (Public Health Scotland, Schottland, 01.03.2022)

https://www.publichealthscotland.scot/publications/national-naloxone-programme-scotland-quarterly-monitoring-bulletin/national-naloxone-programme-scotland-quarterly-monitoring-bulletin-july-to-september-q2-2021-to-2022/